2186.HK2186.HK
Psychiatry40 cited findings · profile updated 2026-08-26
About 2186.HK
2186.HK (2186.HK) focuses on psychiatry. The company's drug LY03004 was associated with an irritability adverse event rate of 4.2%. In the LY03004/CT-USA-102 trial, there were 4 (3.7%) total assessment measurement irregularity deviations, with 2 (3.7%) in the LD group and 2 (3.7%) in the LY03004 group. Another drug, Erzofri, is proposed for schizophrenia and schizoaffective disorder, with a proposed initiation dosing of 351 mg on Day 1 for both indications. The proposed monthly dose for schizophrenia is 39-234 mg, with a maximum monthly dose of 234 mg. For schizoaffective disorder, the proposed monthly dose is 78-234 mg, with a maximum monthly dose of 234 mg. The recommended regulatory action for Erzofri is Approval, with a Review Completion Date of 07/26/2024.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| Irritability adverse event rate | 4.2% | SHANDONG LUYE — Rykindo FDA Review (NDA212849, ORIG 1, 2023), p.195 |
| Recommended Regulatory Action | Approval | LUYE INNOMIND PHARMA — Erzofri FDA Review (NDA216352, ORIG 1, 2024), p.2 |
| Proposed Indication - Schizophrenia Initiation Dosing (Day 1) | 351 mg | LUYE INNOMIND PHARMA — Erzofri FDA Review (NDA216352, ORIG 1, 2024), p.2 |
| Proposed Indication - Schizoaffective disorder Initiation Dosing (Day 1) | 351 mg | LUYE INNOMIND PHARMA — Erzofri FDA Review (NDA216352, ORIG 1, 2024), p.2 |
| LY03010 156 mg Deltoid Cmax | 16.0 ng/Ml | LUYE INNOMIND PHARMA — Erzofri FDA Review (NDA216352, ORIG 1, 2024), p.40 |
| LY03010 156 mg Gluteal Cmax | 11.2 ng/Ml | LUYE INNOMIND PHARMA — Erzofri FDA Review (NDA216352, ORIG 1, 2024), p.40 |
Key projects
- LY03004
LY03004 was associated with an irritability adverse event rate of 4.2%.
- Erzofri (Schizophrenia)
Erzofri has a proposed indication for schizophrenia with a Day 1 initiation dosing of 351 mg and a monthly dose of 39-234 mg.
- Erzofri (Schizoaffective disorder)
Erzofri has a proposed indication for schizoaffective disorder with a Day 1 initiation dosing of 351 mg and a monthly dose of 78-234 mg.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Psychiatry research library →